Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 4 Absolute rate of CKD by ULT exposure

From: Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study

Variable Exposed Unexposed Unadjusted Adjusted*
  n Rate 95% CI n Rate 95% CI Hazard ratio 95% CI Hazard ratio 95% CI
1-Year landmark           
 Overall 674 34.3 31.8, 37.0 4058 23.3 22.6, 24.0 1.47 1.35, 1.59 1.09 0.99, 1.18
 Male 450 26.4 24.1, 28.9 2878 19.8 19.1, 20.5 1.33 1.21, 1.47 1.08 0.98, 1.20
 Female 224 86.7 76.1, 98.9 1180 41.0 38.7, 43.4 2.01 1.74, 2.32 1.11 0.96, 1.29
3-Year landmark
 Overall 549 26.1 24.0, 28.4 2027 19.3 18.4, 20.1 1.35 1.23, 1.49 1.03 0.94, 1.14
 Male 390 20.7 18.8, 22.9 1538 17.5 16.6, 18.4 1.19 1.06, 1.33 0.96 0.85, 1.07
 Female 159 71.1 60.9, 83.1 489 28.3 25.9, 31.0 2.43 2.03, 2.90 1.31 1.09, 1.59
  1. CKD chronic kidney disease, ULT urate-lowering therapy
  2. *Adjusted for age, gender, body mass index, smoking status, diabetes mellitus, treated hypertension, rheumatoid arthritis, heart failure, index of multiple deprivation, myocardial infarction, cerebrovascular disease, peripheral vascular disease, history of hospitalisation, non-steroidal anti-inflammatory drug exposure and baseline serum creatine and uric acid, when not stratified by them. per 10,000 person-years